

Papillary thyroid microcarcinoma: insights from a cohort of 257 thyroidectomized patients

Henrique Cabral Scherer; Paula Fernandes; Rafael Selbach Scheffel, M.D., Ph.D.; André B. Zanella, M.D., Ph.D.; Ana Luiza Maia, M.D., Ph.D.; and Jose Miguel Dora¹, M.D., Ph.D.

Journal: *Endocrine*

Corresponding author:

Jose Miguel Dora, MD, PhD.

Unidade de Tireoide

Hospital de Clínicas de Porto Alegre

Rua Ramiro Barcelos 2350, 90035-003

Porto Alegre, RS, Brazil

Phone: 55-51-3359.8733

Email: jdora@hcpa.edu.br

Supplementary Table 1. Characteristics of 20 PTMC patients with persistent disease after initial treatment.

Patient	Age at diagnosis (years)	Sex	Tumor size (cm)	Metastasis	ATA 2009 risk stratification system	TNM 8	sPOTg (ng/mL) TgAb	RAI (mCi)	Current response to therapy status	Relapse site	Follow up (years)
1	68	F	0.9	No	Low	I NxM0	31.8 / Neg	100	Excellent	None	4.2
2	62	F	0.7	No	Low	I NxM0	NA	0	Indeterminate	None	4.2
3	61	M	0.4	No	Low	I NxM0	NA	30	Indeterminate	None	9.6
4	58	F	0.1	No	Low	I NxM0	73.7 / Neg	0	Biochemical Incomplete	3	2.2
5	50	F	0.4	No	Low	I NxM0	NA	0	Cervical Structural Incomplete	15	19.7
6	45	F	0.6	No	Low	I N0M0	69.7 / Neg	30	Cervical Structural Incomplete	16	0.99
7	44	F	0.7	No	Intermediate	I N1bM0	NA	280	Excellent	None	21.4
8	57	F	0.7	No	Intermediate	II N1bM0	NA	200	Excellent	None	5.9
9	50	F	0.8	No	Intermediate	I N0M0	NA	200	Indeterminate	None	17.2
10	21	M	1.0	No	Intermediate	I N1bM0	121.0 / Neg	400	Indeterminate	None	14.4
11	51	F	0.4	No	Intermediate	I N1bM0	NA	NA	Biochemical Incomplete	None	0.9
12	24	M	0.6	No	Intermediate	I N1bM0	5.4 / Neg	NA	Biochemical Incomplete	None	1.0

13	47	M	0.9	No	Intermediate	I N0M0	NA	100	Biochemical Incomplete	None	13.3
14	47	F	0.4	No	Intermediate	I N1bM 0	87.9 / Positive	200	Biochemical Incomplete	None	5.0
15	18	M	0.9	No	Intermediate	I N1bM 0	125.0 / Neg	100	Biochemical Incomplete	None	6.7
16	17	F	1.0	No	Intermediate	I N1bM 0	NA	100	Cervical Structural Incomplete	Cervical	3.6
17	35	F	0.6	No	Intermediate	I N1bM 0	NA	300	Cervical Structural Incomplete	Cervical	16.2
18	23	F	0.8	No	Intermediate	I N0M0	NA	0	Cervical Structural Incomplete	Cervical	6.1
19	70	M	1.0	No	Intermediate	II N1bM 0	34.2 / Neg	100	Cervical Structural Incomplete	Cervical	3.7
20	40	M	0.4	Lung	High	II N1bM 1	169.5 / Neg	100	Distant Structural Incomplete	Cervical and Lung	2.2

TNM8: 8th edition of the tumor, node, metastases stage.

ATA risk: American Thyroid Association risk.

sPOTg: stimulated postoperative thyroglobulin.

TgAb: anti-thyroglobulin antibody.

NA: not available.

Neg: negative.